Navigation Links
Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
Date:11/20/2012

SEATTLE, Nov. 20, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the 24th Annual Piper Jaffray Health Care Conference next week.  The presentation is scheduled for 9:30 a.m. Eastern Time on Tuesday, November 27, 2012.

The presentation will be webcast. The live and archived webcasts can be accessed on the "Events" page of the Company's website at www.omeros.com.  

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has four ongoing clinical development programs. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets and their corresponding compounds to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Omeros is Not Aware of Any Justification for Share Price Movement
2. Omeros Corporation Reports Third Quarter 2012 Financial Results
3. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
4. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
5. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
6. Omeros to Present at Two Upcoming Conferences
7. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
8. Omeros Corporation Reports Second Quarter 2012 Financial Results
9. Omeros Announces Discovery in MASP-2 Program
10. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
11. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... July 12, 2017 CarpalAID is a revolutionary new product ... surgery. Carpal tunnel syndrome affects more than 8 million ... the rate of men. The common methods of treating CTS are ... uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn on ...
(Date:7/11/2017)... July 11, 2017  Bayer has awarded grants totaling more ... part of its prestigious Bayer Hemophilia Awards Program (BHAP). Four ... Philadelphia and Uniformed Services University of the ... the winners. Grant recipients were announced last night during a ... 2017 Congress, Berlin, Germany . ...
(Date:7/11/2017)... July 11, 2017  Dr. Echenberg, founder of Echenberg Institute, is announcing ... patients who suffer from painful intercourse and other painful pelvic pain conditions ... due to menopause. ... VuVatech LLC ... Sarasota, Florida -based start-up company, VuVatech LLC, fills a ...
Breaking Medicine Technology:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... 4th-year medical students improve their chances of acceptance to a residency in a ... who have earned degrees outside the U.S. , According to data released by ...
(Date:7/21/2017)... ... July 21, 2017 , ... In the first prospective ACL ... Orthopaedics Outcome Network (MOON) demonstrated that patients could perform sports-related functions and maintain ... decline over time. The study, presented today at the American Orthopaedic Society ...
(Date:7/20/2017)... ... , ... ChenMed , a leading provider of value-based care for seniors, ... as Richmond Chief Medical Officer. Dr. McCarter, formerly Associate Professor of Family Medicine ... Ambulatory Services for the UVA Health System, brings 30 years of highly relevant experience ...
(Date:7/20/2017)... ... , ... For individuals with extended hospital stays or who are residents of ... are specially designed to accommodate patients with a wide range of ailments or special ... Ind., has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced ... Proceeds will be used to complete regulatory submissions and fund final engineering and ...
Breaking Medicine News(10 mins):